Sosei Heptares to take back GPCR agonist after GSK changes course
27 Nov 2023
License out/in
Sosei Heptares says it will continue to develop its early-stage oral GPR35 agonistGPR35 agonist after GSK gave the drug back following a decision to stop its own work on the candidate.
Sosei Heptares first licensed the candidate to GSK in 2020 and both companies have since worked on preclinical development. But talks have now begun to return the drug fully to Sosei after changes to GSK’s immunology research strategy and leadership. The company added that the transfer of the license had nothing to do with preclinical data from the candidate.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.